Diagnostic Imaging's Weekly Scan: April 5 — April 11

A combination of time-dependent diffusion MRI-derived parameters and quantitative macromolecular proton fraction (MPF) demonstrated a 96 percent AUC for differentiating high-grade and low-grade cervical cancer, according to newly published research in Academic Radiology.

There was no statistically significant difference in sensitivity rates for lesion detection between breast MRI scans with minimum or mild background parenchymal enhancement (BPE) and those with moderate or marked BPE, according to a newly published study in European Radiology involving over 300 women.

Earlier this week, the Food and Drug Administration (FDA) issued a De Novo classification for neuropacs™, an AI software for 3T diffusion MRI that may enhance differentiation of Parkinson’s disease. The neuropacs™ software provided a 96 percent or better AUROC for differentiating between Parkinson’s disease, atypical parkinsonism, multiple system atrophy Parkinsonian variant and progressive supranuclear palsy, according to a prospective multicenter study published in JAMA Neurology.

In a time-independent test set from a new retrospective study in Insights into Imaging, gadoxetic-acid enhanced MRI provided nearly 38 percent higher sensitivity for detecting sub-centimeter hepatocellular carcinoma recurrence (HCC) in contrast to extracellular contrast agent-enhanced MRI.

For patients with cardiac dysfunction related to neoadjuvant chemotherapy for invasive breast cancer, new MRI research in Academic Radiology shows increased risks for concurrent decreases in total brain volume and white matter volume.